Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report

Ann Acad Med Singap. 2010 Feb;39(2):143-5.

Abstract

Introduction: This study reports a case of bevacizumab administered to treat choroidal neovascularisation in a woman later discovered to be pregnant.

Clinical picture: A 25-year-old pregnant woman developed myopic choroidal neovascularisation in both eyes.

Treatment: Both eyes were treated with a total of 3 intravitreal injections of bevacizumab sequentially.

Outcome: Vision improved significantly in both eyes. There were no evident pregnancy-related complications at 1 year postpartum.

Conclusion: Although anti-vascular endothelial growth factor (VEGF) therapy did not result in any detectable short-term adverse event in this mother and baby, the potential toxicity of these agents must be carefully considered in pregnant patients.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Humans
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab